NO20062357L - Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer - Google Patents

Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer

Info

Publication number
NO20062357L
NO20062357L NO20062357A NO20062357A NO20062357L NO 20062357 L NO20062357 L NO 20062357L NO 20062357 A NO20062357 A NO 20062357A NO 20062357 A NO20062357 A NO 20062357A NO 20062357 L NO20062357 L NO 20062357L
Authority
NO
Norway
Prior art keywords
disease states
cancer
treatment
indoline derivatives
derivatives
Prior art date
Application number
NO20062357A
Other languages
English (en)
Inventor
Monica J Kochanny
Imadul Islam
Wheeseong Lee
Judi Bryant
Richard Feldman
Shendong Yuan
Damian Arnaiz
Yuo-Ling Chou
Paul Hrvatin
Mark Polokoff
Hongyi Yu
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20062357L publication Critical patent/NO20062357L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Indolinonderivater, så som forbindelser med formel (I) hvor A, m, n, R1, R2, R3, R5 og R6 er som beskrevet i beskrivelsen, er anvendelige til behandling av pattedyr med sykdomstilstander som kan lindres ved inhibering av PKD-1-aktivitet.
NO20062357A 2003-10-24 2006-05-23 Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer NO20062357L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51408103P 2003-10-24 2003-10-24
PCT/US2004/035262 WO2005040116A2 (en) 2003-10-24 2004-10-22 Indolinone derivatives and their use in treating disease-states such as cancer

Publications (1)

Publication Number Publication Date
NO20062357L true NO20062357L (no) 2006-07-14

Family

ID=34520168

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062357A NO20062357L (no) 2003-10-24 2006-05-23 Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer

Country Status (14)

Country Link
US (1) US7105563B2 (no)
EP (1) EP1680401A2 (no)
JP (1) JP2007509173A (no)
KR (1) KR20060123184A (no)
CN (1) CN1898205A (no)
AU (1) AU2004284084A1 (no)
BR (1) BRPI0415773A (no)
CA (1) CA2541460A1 (no)
IL (1) IL174788A0 (no)
MX (1) MXPA06004438A (no)
NO (1) NO20062357L (no)
RU (1) RU2006117635A (no)
WO (1) WO2005040116A2 (no)
ZA (1) ZA200604149B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334582A1 (de) * 2003-07-28 2005-02-24 Basf Ag Verfahren zur Herstellung von Maleinsäureanhydrid
MXPA06006049A (es) * 2003-11-26 2007-05-24 Scripps Research Inst Inhibidores de proteina quinasa avanzados a base de indolinona.
DE102005015005A1 (de) * 2005-04-01 2006-10-05 Qiagen Gmbh Verfahren zur Behandlung einer Biomoleküle enthaltenden Probe
WO2007122219A1 (en) * 2006-04-24 2007-11-01 Boehringer Ingelheim International Gmbh 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2008033562A2 (en) 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
JP5452490B2 (ja) 2007-09-06 2014-03-26 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
JP5657524B2 (ja) 2008-04-24 2015-01-21 エフツージー リミテッド ピロール抗真菌剤
WO2010002933A1 (en) * 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
JP2011526615A (ja) * 2008-07-02 2011-10-13 ジェネリクス・（ユーケー）・リミテッド ３−ピロール置換２−インドリノン誘導体の調製
CN101397295B (zh) * 2008-11-12 2012-04-25 深圳微芯生物科技有限责任公司 作为组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物、其制法和用途
EP2246326A1 (de) * 2009-05-02 2010-11-03 Bayer CropScience AG Verfahren zur Herstellung von Oxindolen und ortho-substituierten Anilinen und ihre Verwendung als Zwischenprodukte für Synthesen
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2010303567B2 (en) * 2009-10-06 2016-06-09 Millennium Pharmaceuticals, Inc Heterocyclic compounds useful as PDK1 inhibitors
CN102283826A (zh) * 2010-06-21 2011-12-21 中国医学科学院基础医学研究所 维甲酸及其类似物用于治疗tsc1/tsc2失活或其上游通路活化导致的肿瘤
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
WO2012028162A1 (de) 2010-09-01 2012-03-08 Bayer Cropscience Ag Verfahren zur herstellung von oxindolen und ortho-substituierten anilinen und ihre verwendung als zwischenprodukte für synthesen
AU2010363613B2 (en) 2010-11-01 2015-02-05 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-((pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
CN102688234B (zh) * 2011-03-21 2015-07-29 华东理工大学 吲哚酮衍生物作为rsk2抑制剂的合成与应用
IN2014MN02105A (no) 2012-04-20 2015-09-11 Annji Pharm Co Ltd
HK1220184A1 (zh) * 2013-03-13 2017-04-28 Boston Biomedical, Inc. 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
CN104211632B (zh) * 2013-05-31 2016-12-28 中国人民解放军军事医学科学院放射与辐射医学研究所 具有酪氨酸激酶抑制活性的2‑吲哚酮衍生物及其制备方法与应用
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
WO2016055454A1 (en) * 2014-10-06 2016-04-14 International Society For Drug Development S.R.L. Pharmaceutical combination for the treatment of tumors
AU2015348043B2 (en) 2014-11-21 2019-08-22 F2G Limited Antifungal agents
CA2992945A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途
CN115855899B (zh) * 2022-11-24 2025-06-10 常熟理工学院 一种荧光探针检测二氧化硫衍生物的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5854206A (en) * 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
TR200101745T2 (tr) 1998-12-17 2002-05-21 F.Hoffmann-La Roche Ag 4,5-Azolo-oksindoller
WO2000035921A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
KR20010087421A (ko) 1998-12-17 2001-09-15 프리돌린 클라우스너, 롤란드 비. 보레르 4- 및 5-알키닐옥신돌과 4- 및 5-알케닐옥신돌
CN1136217C (zh) 1998-12-17 2004-01-28 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚
CA2368041A1 (en) 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
EP1259234B9 (en) 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
CA2407799A1 (en) 2000-05-02 2001-11-08 Sugen, Inc. (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP1436259A1 (en) 2001-09-10 2004-07-14 Congxin Liang 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
MXPA04003385A (es) 2001-10-10 2005-04-11 Sugen Inc Derivados de 3-?4-substituido con heterociclilo)-pirrol-2-ilmetilidene?-2-indolinona como inhibidores de cinasa.
US20030119839A1 (en) * 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
KR20050084027A (ko) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
ATE446951T1 (de) * 2003-06-10 2009-11-15 Biondi Ricardo Miguel Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung

Also Published As

Publication number Publication date
WO2005040116A3 (en) 2005-06-16
US7105563B2 (en) 2006-09-12
EP1680401A2 (en) 2006-07-19
MXPA06004438A (es) 2006-06-20
KR20060123184A (ko) 2006-12-01
US20050090541A1 (en) 2005-04-28
CN1898205A (zh) 2007-01-17
CA2541460A1 (en) 2005-05-06
BRPI0415773A (pt) 2006-12-26
ZA200604149B (en) 2007-11-28
AU2004284084A1 (en) 2005-05-06
IL174788A0 (en) 2006-08-20
WO2005040116A2 (en) 2005-05-06
RU2006117635A (ru) 2007-12-10
JP2007509173A (ja) 2007-04-12

Similar Documents

Publication Publication Date Title
NO20081217L (no) Nye benzotiazolonderivater
NO20061194L (no) Mitotiske kinesininbibitorer
TW200637820A (en) Indoles useful in the treatment of inflammation
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20071534L (no) Behandling av inflammatoriske forstyrrelser og smerte
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20074274L (no) Tetrahydroindolon og tetrahydroindazolonderivater
NO20083207L (no) Inhibitorer av IAP
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
TW200637818A (en) Indoles useful in the treatment of inflammation
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
NO20073099L (no) Amino-imidazoloner for inhibering av beta-sekretase
EA200401124A1 (ru) Аминозамещённые (e)-2,6-диалкоксистирил-4-замещённые-бензилсульфоны для лечения пролиферативных расстройств
TW200745004A (en) Novel compounds, their preparation and use
NO20083758L (no) Nye terapautiske kombinasjoner for behandling av depresjon
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20070570L (no) Forbindelser.
MX339668B (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application